Current Drug Discovery Technologies

Editor-in-Chief:
Vladimir P. Torchilin
Department of Pharmaceutical Science Center
for Pharmaceutical Biotechnology and Nanomedicine
Northeastern University
Boston, MA 02115
USA

 

Back

Become EABM
Become Reviewer

Editorial [Hot Topic: New Anticoagulant Drugs: A Change of Paradigm? (Guest Editor: Antonio Gomez-Outes)] promotion: free to download

Volume:9   Issue: 2
Pp: 81-82
Antonio Gomez-Outes
DOI: 10.2174/1570163811209020081

Discovery of Anticoagulant Drugs: A Historical Perspective

Volume:9   Issue: 2
Pp: 83-104
Antonio Gomez-Outes, M Luisa Suarez-Gea, Gonzalo Calvo-Rojas, Ramon Lecumberri, Eduardo Rocha, Carmen Pozo-Hernandez, Ana Isabel Terleira-Fernandez and Emilio Vargas-Castrillon
DOI: 10.2174/1570163811209020083

Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach

Volume:9   Issue: 2
Pp: 105-118
Gonzalo Calvo-Rojas and Antonio Gomez-Outes
DOI: 10.2174/1570163811209020105

New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors

Volume:9   Issue: 2
Pp: 119-128
Cecilia Becattini, Alessandra Lignani and Giancarlo Agnelli
DOI: 10.2174/1570163811209020119

New Parenteral Anticoagulants: Focus on Factor Xa and Thrombin Inhibitors

Volume:9   Issue: 2
Pp: 129-136
Ingo Ahrens and Christoph Bode
DOI: 10.2174/1570163811209020129

Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins

Volume:9   Issue: 2
Pp: 137-142
Alfredo Garcia-Arieta and Antonio Blazquez
DOI: 10.2174/1570163811209020137

Reversing Anticoagulant Therapy

Volume:9   Issue: 2
Pp: 143-149
Shari Ghanny, Theodore E. Warkentin and Mark A. Crowther
DOI: 10.2174/1570163811209020143

New Targets for Anticoagulation and Future Perspectives

Volume:9   Issue: 2
Pp: 150-155
Jack Ansell and David Askin
DOI: 10.2174/1570163811209020150